CN111991662A - Intelligent system for automatically providing oxygen treatment scheme - Google Patents
Intelligent system for automatically providing oxygen treatment scheme Download PDFInfo
- Publication number
- CN111991662A CN111991662A CN202010958090.0A CN202010958090A CN111991662A CN 111991662 A CN111991662 A CN 111991662A CN 202010958090 A CN202010958090 A CN 202010958090A CN 111991662 A CN111991662 A CN 111991662A
- Authority
- CN
- China
- Prior art keywords
- value
- flow
- oxygen
- carbon dioxide
- tcs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/202—Blood composition characteristics partial carbon oxide pressure, e.g. partial dioxide pressure (P-CO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/205—Blood composition characteristics partial oxygen pressure (P-O2)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P90/00—Enabling technologies with a potential contribution to greenhouse gas [GHG] emissions mitigation
- Y02P90/02—Total factory control, e.g. smart factories, flexible manufacturing systems [FMS] or integrated manufacturing systems [IMS]
Abstract
The invention relates to medical equipment, in particular to an intelligent system for automatically providing an oxygen treatment scheme, which mainly comprises a data model analysis control unit, a percutaneous blood oxygen saturation (tcs 02) monitoring unit, a carbon dioxide end-tidal (PETCO2) monitoring unit, a data model analysis control unit, a flow numerical control unit, a human-computer interaction interface and a communication transmission unit. The method automatically provides an adjusted oxygen therapy scheme, a blood oxygen saturation interval value, a suction flow correction interval, a flow correction interval and an output flow, so that the dynamic transcutaneous oxygen saturation (tcs 02) value, the end-tidal carbon dioxide (PETCO2) interval value, the transcutaneous oxygen partial pressure (tcpO 2) interval value and the transcutaneous carbon dioxide partial pressure (tcpCO 2) interval value of a patient are accurately controlled in a reasonable target transcutaneous oxygen saturation (tcs 02) control interval value, and the effectiveness and the safety of oxygen therapy are improved.
Description
Technical Field
The invention relates to medical equipment, in particular to an intelligent system for automatically providing an oxygen treatment scheme.
Background
Oxygen inhalation therapy (oxygen therapy for short) is one of the most common rescue or treatment means in hospitals, and aims to improve the oxygen-deficient state of an organism by inhaling oxygen to a patient. At present, the oxygen therapy is understood shallowly in China, the whole oxygen therapy process is lack of strict monitoring and necessary flow regulation measures, specific oxygen therapy target blood oxygen values are not given, the hypoxia type of a patient is difficult to find in time, and systematic and scientific oxygen therapy measures cannot be carried out.
The general basic vital signs at present are body temperature, pulse, respiration, blood pressure, blood oxygen saturation, and end-tidal carbon dioxide PETCO2, wherein the blood oxygen saturation and the end-tidal carbon dioxide PETCO2 are suggested as a "fifth vital sign" and a "sixth vital sign" (british thoracic association (BTS) emergency oxygen therapy guideline (2008 edition)), there are currently on the market intelligent oxygen therapy systems using target blood oxygen saturation as a control point, but the method for adjusting oxygen flow only using the blood oxygen saturation as a parameter has obvious defects: 1. whether the patient has carbon dioxide retention or not cannot be judged only by the blood oxygen saturation value, and reasonable oxygen therapy advice and initial oxygen flow cannot be given; 2. when the patient's condition is progressive, carbon dioxide retention occurs, and the oxygen saturation of blood is reduced, if the initial flow is a medium flow, the flow is adjusted to be 4L/min at most, and the patient will have oxygen poisoning symptoms, even coma and death. 3. When the illness condition of a patient is gradually aggravated, the oxygen saturation degree is monitored independently, the hypoxia type of the patient at the stage cannot be distinguished quickly and accurately, and the oxygen therapy scheme cannot be adjusted in time, so that the oxygen therapy scheme is required to be adjusted quickly by adopting double monitoring of a percutaneous oxygen saturation degree (TcSO 2) monitoring unit and a carbon dioxide end-expiratory (PETCO2) monitoring unit and combining other vital signs of the patient to quickly identify the hypoxia type, and the oxygen therapy scheme can be adjusted quickly to achieve real safe oxygen therapy, controllable oxygen therapy and intelligent oxygen therapy.
Disclosure of Invention
In view of the above-mentioned drawbacks of the background art, the present invention provides an intelligent system for automatically providing an oxygen therapy plan, which makes up for the deficiencies of the prior art.
The technical scheme of the invention is realized as follows:
an intelligent system for automatically providing an oxygen therapy regimen, comprising: the system mainly comprises a data model analysis control unit, a percutaneous blood oxygen saturation (tcs 02) monitoring unit, a carbon dioxide end-expiratory (PETCO2) monitoring unit, a data model analysis control unit, a flow numerical control unit, a man-machine interaction interface and a communication transmission unit, wherein a control data model is arranged in the data model analysis control unit, and the construction elements of the analysis control data model comprise but are not limited to an oxygen treatment scheme, a target percutaneous blood oxygen saturation (tcs 02) value, a percutaneous blood oxygen saturation (tcs 02) allowable deviation value, a percutaneous blood oxygen saturation (tcs 02) interval value, a carbon dioxide end-expiratory (PETCO2) value, a carbon dioxide end-expiratory (PETCO2) interval value, an initial flow value, intervention time, a flow correction interval and a flow correction gradient (index); specific data models of an oxygen treatment scheme, a target percutaneous blood oxygen saturation (tcs 02) value, a percutaneous blood oxygen saturation (tcs 02) allowable deviation value, a percutaneous blood oxygen saturation (tcs 02) interval value, a target end-tidal carbon dioxide (PETCO2) value, a target end-tidal carbon dioxide (PETCO2) interval value, an initial flow value, intervention time, a flow correction interval and a flow correction gradient (index) in the elements of the data model analysis control unit are preset in the data model analysis control unit, and the percutaneous blood oxygen saturation (tcs 02) value, the percutaneous blood oxygen saturation (tcs 02) allowable deviation value, the percutaneous blood oxygen saturation (tcs 02) interval value, the end-tidal carbon dioxide (PETCCO 2) value, the end-tidal carbon dioxide (PETCCO 2) interval value, the initial flow value and the oxygen inhalation time length can be set in a man-machine interaction interface in a personalized mode according to the state of a patient; the human-computer interaction interface at least comprises a target percutaneous blood oxygen saturation (tcs 02) setting key (or a touch screen key), a carbon dioxide end-tidal (PETCO2) value setting key (or a touch screen key), an oxygen inhalation time length setting key (or a touch screen key), a flow setting key (or a touch screen key), a low perfusion mode key (or a touch screen key), an oxygen therapy scheme selection key (or a touch screen key),
furthermore, a percutaneous oxyhemoglobin saturation (tcs 02) interval value and a carbon dioxide end-of-expiration (PETCO2) interval value are preset in a data model analysis control unit, the method can automatically display the current hypoxia type on a human-computer exchange interface, judge whether carbon dioxide retention exists or not, give an oxygen treatment scheme, a suggested oxyhemoglobin saturation interval value and an oxygen inhalation flow correction interval value, and only need to set and select a reasonable oxygen treatment scheme on the human-computer exchange interface; the flow correction interval is divided into three regulation intervals of a low flow area, a medium flow area and a high flow area, a flow correction interval value is arranged in the data model, and as long as an initial flow value is set on a human-computer interaction interface, a reasonable oxygen treatment scheme is selected, and the data model analysis control unit automatically matches the corresponding flow correction interval and a transcutaneous oxygen saturation (tcs 02) interval value;
the data model analysis control unit is internally provided with a tertiary oxygen therapy scheme, wherein the end-tidal carbon dioxide (PETCO2) value is normal, when the end-tidal carbon dioxide is not hypoperfused, the primary oxygen therapy scheme is started, when the end-tidal carbon dioxide value is abnormal and is higher than 6kpa (45mmhg), the secondary oxygen therapy scheme is started, when the patient has hypoperfusion symptoms, a hypoperfusion mode key (or a touch screen key) is pressed, the tertiary oxygen therapy scheme is started, and a transcutaneous blood oxygen saturation (tcs 02) monitoring unit and an end-tidal carbon dioxide (PETCO2) monitoring unit are used for doubly and continuously monitoring the dynamic transcutaneous blood oxygen saturation (tcs 02) value and the end-tidal carbon dioxide (PETCO2) value of the patient;
1. if the end-tidal carbon dioxide (PETCO2) value is normal, 4.6kpa (35mmhg) is more than or equal to Petco2 is more than or equal to 6kpa (45mmhg), the value of the percutaneous blood oxygen saturation (tcs 02) is less than or equal to 94%, the system judges that the patient is hypotonic hypoxia and does not accompany hypercapnia, and at the moment, the primary oxygen therapy scheme maintains the initial flow rate when the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient is stably kept in the control interval value; when the dynamic percutaneous blood oxygen saturation (tcs 02) value exceeds the upper limit of the control interval value and reaches the intervention time, the flow automatic gradient is reduced; when the dynamic percutaneous blood oxygen saturation (tcs 02) value is lower than the lower limit of the control interval value and the intervention time is reached, the flow automatic gradient is increased, so that the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient is stably kept in the control interval value, and the aim of accurately controlling oxygen therapy is fulfilled; when the oxygen output is adjusted to the maximum value or the minimum value and is kept for 30min, but the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient still deviates from the control interval value, the data model analysis control unit gives out warning information and a suggested oxygen therapy scheme, the medical staff executes the suggested oxygen therapy scheme after confirming, and can also set manually, the warning information can be prompted on a human-computer interaction interface, can be displayed on a clinical monitoring terminal, and can also be displayed simultaneously;
2. when the end-tidal carbon dioxide (PETCO2) value exceeds the critical value and is more than 6kpa (45mmhg), the value of the percutaneous blood oxygen saturation (tcs 02) is less than or equal to 94 percent, the system judges that the patient is anoxic and hypercapnia and automatically switches to a secondary oxygen treatment scheme taking the end-tidal carbon dioxide (PETCO2) value as the leading factor; the flow correction interval is adjusted to be a low flow area;
3. if the patient has low perfusion symptoms such as microcirculation disturbance, heart failure, myocardial infarction, shock and the like, a three-level oxygen treatment scheme is manually selected:
a. if the end-tidal carbon dioxide (PETCO2) value is more than 6kpa (45mmhg), whether the percutaneous blood oxygen saturation (tcs 02) interval is stable or not, the system automatically selects an oxygen treatment scheme of tissue hypoxia (or circulatory hypoxia) with hypercapnia, and the flow correction interval is adjusted to be a low flow area;
b. the system automatically selects an oxygen treatment regimen for interstitial hypoxia (or circulatory hypoxia) without hypercapnia during the period when the value of percutaneous blood oxygen saturation (tcs 02) stabilizes at > 90% and the value of end-tidal carbon dioxide (PETCO2) stabilizes at < 6kpa (45 mmhg); the flow correction interval is adjusted to be a low flow area;
c. when the value of percutaneous blood oxygen saturation (tcs 02) is less than 90%, the value of 4.6kpa (35mmhg) < the value of end-tidal carbon dioxide (PETCO2) < 6kpa (45mmhg), the system automatically selects an oxygen treatment scheme with histochemical hypoxia (or circulatory hypoxia) and hypotonic hypoxia without hypercapnia, and the flow correction interval is adjusted to be a medium-flow area;
d. when the value of percutaneous blood oxygen saturation (tcs 02) is less than 90%, the value of end-tidal carbon dioxide (PETCO2) is more than 6kpa (45mmhg), and the state is stably kept for 1-5 min, the system automatically selects an oxygen treatment scheme flow correction interval with histochemical hypoxia (or circulatory hypoxia) and low-tension hypoxia accompanied by hypercapnia to adjust the flow correction interval to a low-flow area or automatically restores the output flow value to an initial set flow value, automatic intervention regulation of output flow is stopped, the data model analysis control unit gives warning information to prompt medical personnel to correct the oxygen treatment scheme, and the warning information is prompted or remotely transmitted to a clinical monitoring terminal on a human-computer interaction interface;
4. the data model analysis control unit is internally provided with a blood liquid hypoxia mode, is set to be used for medium-flow oxygen therapy (the flow value of medical advice is 3L/min-4L/min), and the flow correction interval is defined to be 0.1L/min-4L/min, so that the blood gas change is special, but the clinical judgment is easy, and only a nursing staff needs to select the mode when in use;
5. a data model analysis control unit is internally provided with a neonate mode, low-flow oxygen therapy (the flow value of medical advice is between 0.5L/min and 2L/min) is set, and a flow correction interval is defined to be between 0.1L/min and 2L/min;
6. when the end-tidal carbon dioxide (PETCO2) value is less than the critical value < 4.6kpa (35mmhg), the gradient is adjusted to the highest value of the interval flow, and if the initial flow interval is a low flow area, the gradient is automatically adjusted to a medium flow area; or stopping automatic intervention regulation of output flow, giving out warning information by the data model analysis control unit to prompt medical personnel to correct the oxygen treatment scheme, and prompting or remotely transmitting the warning information to a clinical monitoring terminal on a human-computer interaction interface;
during oxygen therapy, if a percutaneous oxyhemoglobin saturation (tcs 02) monitoring unit and a carbon dioxide at end of expiration (PETCO2) monitoring unit work abnormally, including and not limited to the fact that a probe falls off from a monitoring part, the probe is damaged, and a blood oxygen value cannot be normally obtained, a sampling tube is blocked or distorted due to secretion, a data model analysis control unit automatically restores an output flow value to an initial flow value which is initially set, automatic intervention is stopped to adjust the output flow, potential safety hazards are avoided, and meanwhile warning information is sent to prompt medical personnel to check.
Furthermore, a data model analysis control unit of a percutaneous oxyhemoglobin saturation (tcs 02) monitoring unit and a carbon dioxide at end of expiration (PETCO2) monitoring unit is established, the current hypoxia type of a patient is intelligently judged, whether carbon dioxide retention exists or not is intelligently judged, a reasonable oxygen treatment scheme is selected, a recommended oxyhemoglobin saturation interval value and an oxygen inhalation flow correction interval value are selected, and medical staff only need to select the reasonable oxygen treatment scheme on a human-computer interaction interface; the initial oxygen flow and the oxygen treatment duration are only needed, when the state of an illness develops progressively, an oxygen treatment scheme adjustment suggestion can be automatically provided, warning information is sent out at the same time, medical staff are prompted to correct the oxygen treatment scheme, and the warning information is prompted or remotely transmitted to a clinical monitoring terminal on a human-computer interaction interface.
Further, an electronic encoder is adopted by a target transcutaneous oxygen saturation (tcs 02) value setting key (or a touch screen key), a carbon dioxide end-tidal (PETCO2) value setting key (or a touch screen key), an oxygen inhalation time length setting key (or a touch screen key), a flow setting key (or a touch screen key), a low perfusion mode key (or a touch screen key) and an oxygen therapy scheme selection key; virtual keys can also be arranged on the microcomputer touch screen.
Further, the data model analysis control unit takes the individualized target percutaneous blood oxygen saturation (tcs 02) value, the end-tidal carbon dioxide (PETCO2) value and the oxygen treatment scheme selection key as three-level control units, the given target percutaneous blood oxygen saturation (tcs 02) value is provided with an allowable deviation value, and the target percutaneous blood oxygen saturation (tcs 02) allowable deviation value is in the range of the allowable deviation value+1%～+Defined between 3%; the values of end-tidal carbon dioxide (PETCO2) are given in the interval 4.6kpa (35mmhg) < end-tidal carbon dioxide (PETCO2) < 6kpa (45 mmhg).
Further, controlling the intervention time to be set within 0-60 min; preferably, the intervention time is calculated by taking the stable time of the dynamic percutaneous oxygen saturation (tcs 02) value and the end-expiratory carbon dioxide (PETCO2) interval value as a basis, when the dynamic percutaneous oxygen saturation (tcs 02) value overrides the control interval value and the state is stably maintained for 1-5 min, the data model analysis control unit reduces the oxygen output flow, when the dynamic percutaneous oxygen saturation (tcs 02) value is lower than the target percutaneous oxygen saturation (tcs 02) control interval value and the state is stably maintained and maintained for 0.5-3 min, the data model analysis control unit increases the oxygen output flow, and when the end-expiratory carbon dioxide (PETCO2) interval value is stably maintained for 10min, the oxygen treatment scheme of oxygen deficiency with hypercapnia is overridden.
Furthermore, when the end-tidal carbon dioxide (PETCO2) value is normal, 4.6kpa (35mmhg) is more than or equal to Petco2 is more than or equal to 6kpa (45mmhg), the value of percutaneous blood oxygen saturation (tcs 02) is less than or equal to 94%, the system judges that the patient is low-tension hypoxia and does not accompany hypercapnia, the data model analysis control unit automatically matches the corresponding flow correction interval and blood oxygen saturation interval value according to the set initial flow value and the selected oxygen treatment scheme, and the data model analysis control unit intervenes in automatic adjustment of the output flow of oxygen, strictly controls the upper limit and the lower limit of the output flow in the flow correction interval, and does not break through during automatic adjustment.
Further, when the end-tidal carbon dioxide (PETCO2) value is greater than 6kpa (45mmhg) and the condition is maintained stably for 5min, the system judges that the patient is hypotonic hypoxia with hypercapnia, for example, the initial flow rate is in a medium flow rate or high flow rate region, and the flow rate reduction gradient is adjusted to 2L/min, for example, the initial flow rate is in a low flow rate region, and the flow rate reduction gradient is adjusted to 0.5L/min.
Further, if the patient has low perfusion symptoms of microcirculation disturbance such as heart failure, myocardial infarction, shock and the like, a three-level oxygen treatment scheme is manually selected:
a. if the end-tidal carbon dioxide (PETCO2) value is more than 6kpa (45mmhg), whether the percutaneous blood oxygen saturation (tcs 02) interval is stable or not, the system automatically selects an oxygen treatment scheme of tissue hypoxia (or circulatory hypoxia) with hypercapnia, and the flow correction interval is adjusted to be a low flow area;
b. when the value of percutaneous blood oxygen saturation (tcs 02) is stable and is more than 90 percent and the value of end-tidal carbon dioxide (PETCO2) is stable and is less than 6kpa (45mmhg), the system automatically selects an oxygen treatment scheme that tissue hypoxia (or circulatory hypoxia) is not accompanied by hypercapnia, and the flow correction interval is adjusted to be a low flow area;
c. when the value of percutaneous blood oxygen saturation (tcs 02) is less than 90%, the value of 4.6kpa (35mmhg) < the value of end-tidal carbon dioxide (PETCO2) < 6kpa (45mmhg), the system automatically selects an oxygen treatment scheme with histochemical hypoxia (or circulatory hypoxia) and hypotonic hypoxia without hypercapnia, and the flow correction interval is adjusted to be a medium-flow area;
d. when the value of percutaneous blood oxygen saturation (tcs 02) is less than 90%, the value of end-tidal carbon dioxide (PETCO2) is more than 6kpa (45mmhg), and the state is stably kept for 1-5 min, the system automatically selects an oxygen treatment scheme flow correction interval with histochemical hypoxia (or circulatory hypoxia) and hypo-hypoxia accompanied by hypercapnia to adjust the flow correction interval to a low flow area or automatically restores the output flow value to an initial set flow value, automatic intervention regulation of output flow is stopped, the data model analysis control unit gives warning information to prompt medical personnel to correct the oxygen treatment scheme, and the warning information is prompted or remotely transmitted to a clinical monitoring terminal on a human-computer interaction interface.
Furthermore, the data model analysis control unit of the invention is internally provided with a blood liquid hypoxia mode, which is set as a medium-flow oxygen therapy (the flow value of the doctor advice is 3L/min-4L/min), the flow correction interval is defined as 0.1L/min-4L/min, the blood gas change is special due to the blood hypoxia, but the clinical judgment is easy, and only the nursing staff needs to select the mode when in use.
Furthermore, the data model analysis control unit is internally provided with a newborn mode, low-flow oxygen therapy (the flow value of the doctor advice is between 0.5L/min and 2L/min) is set, and the flow correction interval is defined to be between 0.1L/min and 2L/min.
Furthermore, when the end-tidal carbon dioxide (PETCO2) value is less than the critical value < 4.6kpa (35mmhg), the gradient is adjusted to the highest value of the interval flow, if the initial flow interval is a low flow area, the gradient is automatically adjusted to a medium flow area, or the automatic intervention is stopped to adjust the output flow, the data model analysis control unit gives out warning information to prompt medical personnel to correct the oxygen treatment scheme, and the warning information is prompted or remotely transmitted to a clinical monitoring terminal on a human-computer interaction interface.
Further, the flow correction interval is divided into three adjustment intervals, namely a low flow area, a medium flow area and a high flow area, and specifically comprises the following steps: during low-flow oxygen treatment (the flow value of the doctor's advice is between 0.5L/min and 2L/min), the flow correction interval is defined to be between 0.1L/min and 2L/min, during medium-flow oxygen treatment (the flow value of the doctor's advice is between 3L/min and 4L/min), the flow correction interval is defined to be between 0.1L/min and 4L/min, and during high-flow oxygen treatment (the flow value of the doctor's advice is between 5L/min and 8L/min), the flow correction interval is defined to be between 0.1L/min and 8L/min.
Furthermore, the flow correction gradient is a flow value which is increased or decreased in each adjustment during the intervention flow adjustment, and the flow correction gradient is defined to be between 0.1L/min and 1L/min in a limited oxygen flow correction interval.
Further, it is preferable that the parameter setting range of each of the construction elements of the control data model of the data model analysis control unit is a range in which the target percutaneous blood oxygen saturation level preset in the control data model is set(tcs 02) allowable deviation value of+1%, intervention time, wherein the flow is reduced by 3min and the flow is increased by 0.5 min; the flow correction interval is defined as 0.5L/min-2L/min during low flow oxygen therapy (between 0.5L/min-2L/min), 1L/min-4L/min during medium flow oxygen therapy (between 3L/min-4L/min), and 1L/min-8L/min during high flow oxygen therapy (between 5L/min-8L/min); the flow correction gradient is 0.5L/min; the target percutaneous blood oxygen saturation (tcs 02) value, the initial flow value and the oxygen treatment duration are set individually according to individual difference and hypoxia degree of patients on a man-machine interaction interface.
Further, when the value of the end-tidal carbon dioxide (PETCO2) exceeds a preset value and is higher than 10.6KPa (80 mmHg), the control data model is automatically switched into a secondary analysis control data model taking the value of the end-tidal carbon dioxide (PETCO2) as the leading factor, the flow correction interval of the end-tidal carbon dioxide (PETCO2) which is higher than 6KPa (45mmHg) is automatically defined to be 0.1L/min-2L/min, the intervention time is defined by 0.5min when the flow is reduced, and the increased flow is defined by 3 min; the flow correction gradient is 0.5L/min; the flow correction interval of the end-expiratory carbon dioxide (PETCO2) lower than 4kPa (30 n1 mHg) is automatically defined as 3L/min-4L/min, the flow is reduced by 3min, the flow is increased by 0.5min, and the flow correction gradient is 1L/min.
Furthermore, the data model analysis control unit writes common oxygen treatment schemes of different hypoxia types and mixed hypoxia types into the control data model, medical staff only need to set and select a reasonable oxygen treatment scheme, initial oxygen flow and oxygen treatment duration on a human-computer interaction interface, and the data model analysis control unit automatically gives other factors such as a suggested blood oxygen saturation degree interval value and an oxygen uptake flow correction interval value for the medical staff to select and apply; of course, according to individual differences of patients, medical staff can modify specific parameters such as oxygen inhalation flow value, oxygen inhalation time length and the like given by the data model analysis control unit at a human-computer interaction interface, and a more optimized and safer personalized treatment scheme is provided.
The invention has the beneficial effects that: automatically displaying the oxygen deficiency type on a human-computer interaction interface according to the characteristics of the patient, giving a suggested oxygen therapy scheme, a blood oxygen saturation interval value, an oxygen uptake flow correction interval value and providing for medical care personnel to select and apply; when the disease condition develops progressively, the invention can automatically display the current hypoxia type, whether carbon dioxide retention occurs or not, automatically provide an adjusted oxygen therapy scheme, a blood oxygen saturation interval value and an oxygen uptake flow correction interval, and the values are selected and applied by medical workers; if the patient has microcirculation disturbance such as heart failure, myocardial infarction, shock and other low perfusion symptoms, the medical personnel can select a three-level oxygen therapy scheme on the human-computer interaction interface; after the medical advice flow value and the oxygen inhalation duration are set, the data model analysis control unit intelligently controls the oxygen therapy working state according to a pre-written data model, judges the current hypoxia type, automatically provides an adjusted oxygen therapy scheme, a blood oxygen saturation interval value and an oxygen inhalation flow correction interval, monitors the matching state of a dynamic percutaneous blood oxygen saturation (tcs 02) interval value, a carbon dioxide at end of expiration (PETCO2) interval value, a target percutaneous blood oxygen saturation (tcs 02) value and a target carbon dioxide at end of expiration (PETCO2) interval value, and automatically judges the current hypoxia type and whether the carbon dioxide retention risk exists when the dynamic channel value deviates from the target value control interval value and reaches the intervention control time; the method automatically provides an adjusted oxygen therapy scheme, a blood oxygen saturation interval value, a suction flow correction interval, a flow correction interval and an output flow, so that the dynamic transcutaneous oxygen saturation (tcs 02) value, the end-tidal carbon dioxide (PETCO2) interval value, the transcutaneous oxygen partial pressure (tcpO 2) interval value and the transcutaneous carbon dioxide partial pressure (tcpCO 2) interval value of a patient are accurately controlled in a reasonable target transcutaneous oxygen saturation (tcs 02) control interval value, and the effectiveness and the safety of oxygen therapy are improved.
Drawings
FIG. 1 is a block diagram of the working principle of the present invention;
fig. 2 is a block diagram of the operation of the present invention.
Detailed Description
Example 1: further exemplified in connection with the "hypoxic type" of table 1 according to clinical practice.
The hypoxia type was defined as: 1. hypoxia without hypercapnia 2, hypoxia with hypercapnia 3, hypoxia/circulatory hypoxia a, tissue hypoxia/circulatory hypoxia with hypercapnia b, tissue hypoxia/circulatory hypoxia without hypercapnia c, tissue hypoxia/circulatory hypoxia with hypercapnia d, tissue hypoxia/circulatory hypoxia with hypocapnia 4, blood hypoxia 5, neonatal hypoxia
According to clinical needs, the oxygen therapy scheme is set as the following 6 (4 subspecies) alternative treatment schemes, wherein the treatment scheme numbers (1) to (9) can start the oxygen therapy as long as the initial flow value and the oxygen inhalation time length are set.
(1) Hypoxia without hypercapnia: for conventional oxygen inhalation patients such as cancer patients and patients with anesthesia resuscitation, the value of the target percutaneous blood oxygen saturation (tcs 02) of oxygen therapy is set to 96%, and the allowable deviation value is + 1%; the oxygen inhalation flow correction interval value is set as the middle flow
(2) Hypoxia with hypercapnia: the target transcutaneous oxygen saturation (tcs 02) value for oxygen therapy was set to 90%, the allowable deviation value was + 1%; the oxygen inhalation flow correction interval value is set to be low flow
(3) Sexual/circulatory hypoxia
a. Tissue hypoxia (or circulatory hypoxia) with hypercapnia: such as shock, cardiac dysfunction, cardiovascular and cerebrovascular accidents, with a value of 92% and a tolerance deviation of + 1%; setting the oxygen inhalation flow correction interval value as low flow;
b. the value for the histochemical hypoxia (or circulatory hypoxia) is set to 92% without hypercapnia, the allowable deviation value is + 1%; setting the oxygen inhalation flow correction interval value as a medium flow;
c. tissue hypoxia (or circulatory hypoxia) combined with hypotonic hypoxia: with hypercapnia: such as shock, cardiac dysfunction, cardiovascular and cerebrovascular accidents, with a value of 92% and a tolerance deviation of + 1%; the oxygen inhalation flow correction interval value is set to be low flow
d. Tissue hypoxia (or circulatory hypoxia) and hypotonic hypoxia without hypercapnia, the value was set at 92%, the allowable deviation was + 1%; setting the oxygen inhalation flow correction interval value as a medium flow;
(4) blood hypoxia: set to 96%, the allowable deviation value is + 1%; setting the oxygen inhalation flow correction interval value as high flow;
(5) the target transcutaneous oxygen saturation (tcs 02) value for neonatal oxygen therapy was set to 93%, the allowable deviation value was + 1%;
(6) the target transcutaneous oxygen saturation for oxygen therapy (tcs 02) value for patients with acute respiratory distress syndrome was set to 92%, with an allowable deviation value of + 1%; setting the oxygen inhalation flow correction interval value as high flow;
2. setting an initial flow value: 5-6L/min for anesthesia resuscitation patients, wherein the prescribed flow value of conventional patients is generally set between 3-4L/min, the prescribed flow value of neonatal oxygen therapy is set between 0.5-1L/min, and the prescribed flow value of oxygen therapy for patients with partial pressure of carbon dioxide at the end of expiration higher than 6kpa (45mmhg) or lower than 4.6kpa (35mmhg), patients with acute respiratory distress syndrome and patients with risk of hypercapnia is set between 1-2L/min.
3. Intervention control time definition:
(1) reducing flow intervention control time: and 3min, when the dynamic percutaneous blood oxygen saturation (tcs 02) value and the end-tidal carbon dioxide (PETCO2) value exceed the target percutaneous blood oxygen saturation (tcs 02) control interval value and are stably maintained for 3min, reducing the oxygen output flow.
(2) And (3) increasing flow intervention control time: and 1min, and increasing the oxygen output flow when the dynamic percutaneous blood oxygen saturation (tcs 02) value is lower than the target percutaneous blood oxygen saturation (tcs 02) control interval value and is stably maintained for 3 min.
4. Flow correction gradient definition: in the oxygen flow correction interval, the whole gradient is adjusted to be 0.5L/min when the flow is reduced, the gradient is adjusted to be 1L/min when the flow is increased, and the gradient is adjusted every time one intervention control time unit is reached until the upper limit or the lower limit of the oxygen flow correction interval. When the end-tidal carbon dioxide (PETCO2 value exceeds a preset value and is higher than 6kPa (45mmhg)1 or lower than 4kPa (30 n1 mmhg), and the state is kept stably for 1-5 min, automatically switching to a secondary oxygen therapy scheme which is dominated by the end-tidal carbon dioxide (PETCO2) value, when the flow correction interval is automatically defined to be 0.1L/min-2L/min when the state is kept stably for 1-5 min and when the flow correction interval is higher than 6kPa (45mmhg), if the initial flow is in a medium flow or high flow region, the flow is reduced by 0.5L/0.5min, the flow reduction gradient is adjusted to 2L/min, if the initial flow is in a low flow region, the flow is reduced by 0.5L/0.5min, the flow reduction gradient is adjusted to 0.5L/min, if the partial pressure value of the carbon dioxide is lower than 4.6kPa (35mmhg), and when the state is kept stably for 1-5 min, the flow correction interval is defined as the flow control gradient of the flow control interval of the flow control gradient is adjusted to 0.5L/min If the initial flow interval is a low flow area, the flow maximum value is automatically adjusted to be a medium flow area. When the value of the percutaneous blood oxygen saturation (tcs 02) and the value of the end-tidal carbon dioxide (PETCO2) are stable, if the patient has low perfusion symptoms of microcirculation disturbance such as heart failure, myocardial infarction, shock and the like, a three-level oxygen therapy scheme is manually selected; the gradient is adjusted to the highest value of interval flow, if the initial flow interval is a low flow area, the gradient is automatically adjusted to a medium flow area
5. Oxygen flow correction interval: automatically matching three intervals according to the flow value of the medical advice: 0.1L-2 when the doctor orders are in low flow; 1-4 times of medium-flow medical advice; high flow medical advice time 1 ~ 8.
Table 1: and each construction element and specific parameter list of the data model analysis control unit.
In combination with table 12In line, oxygen therapy protocol (1) with the target transcutaneous oxygen saturation (tcs 02) value set at 96% is further illustrated. The target percutaneous blood oxygen saturation (tcs 02) value set for the patient on the human-computer interaction interface is 96%, the medical order flow value is set to be three parameters of 5L/min of high-flow oxygen inhalation and 5h of oxygen inhalation duration. The data model analysis control unit automatically defines the control interval value of the target percutaneous blood oxygen saturation (tcs 02) between 95% and 97%, and the oxygen flow correction interval is automatically defined between 1L/min and 8L/min. Entering an oxygen therapy mode after setting is finished, dynamically monitoring the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient by a percutaneous blood oxygen saturation (tcs 02) monitoring module, maintaining the medical flow value when the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient is stably kept between 95% and 97%, and exceeding the target percutaneous blood oxygen saturation (tcs 02) value when the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient) When the upper limit of the control interval value is 97% and the duration reaches 3min, the control system gives an instruction for reducing the oxygen output flow, the flow regulating valve automatically reduces the oxygen output quantity, the gradient is reduced to 0.5L/min every time, and the gradient is reduced every 3min until the minimum value of the oxygen flow correction interval; if the dynamic percutaneous blood oxygen saturation (tcs 02) value of the patient is 95% lower than the lower limit of the control interval value of the target percutaneous blood oxygen saturation (tcs 02) and the duration reaches 1min, the control system gives an instruction of increasing the oxygen output flow within 0.5min, the flow regulating valve automatically regulates the oxygen output, the gradient is regulated to be 1L/min every time, and the gradient is regulated to be higher every 0.5min until the maximum value of the oxygen flow correction interval. When the oxygen output is adjusted to the maximum value or the minimum value, but the dynamic transcutaneous oxygen saturation (tcs 02) value of the patient still deviates from the target transcutaneous oxygen saturation (tcs 02) control interval value, the data model analysis control unit gives out warning information, and the warning information is prompted or remotely transmitted to a clinical care terminal on a human-computer interaction interface to prompt medical personnel to perform manual intervention; when the end-tidal carbon dioxide (PETCO2) value is higher than 6kpa (45mmhg)1 and the state is stably kept for 3min, the two-stage analysis control data model taking the end-tidal carbon dioxide (PETCO2) value as the leading part is automatically switched, as the initial flow is in a high-flow area, the flow rate is reduced at 0.5L/0.5min, the flow rate reduction gradient is adjusted to 2L/min, and after the set oxygen inhalation time is up to 5h, the flow control valve is automatically closed, and the control system prompts the end of the oxygen therapy.
The drawings and the embodiments are only for illustrating the technical solution of the present invention and not for limiting the same. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art will appreciate that various modifications and equivalent arrangements can be made without departing from the spirit and scope of the present invention, which is to be covered by the appended claims.
TABLE 1
Claims (17)
1. An intelligent system for automatically providing an oxygen treatment scheme mainly comprises a data model analysis control unit, a percutaneous blood oxygen saturation (tcs 02) monitoring unit, a carbon dioxide end-tidal (PETCO2) monitoring unit, a data model analysis control unit, a flow numerical control unit, a human-computer interaction interface and a communication transmission unit, and is characterized in that: the data model analysis control unit is provided with a control data model, and analysis control data model construction elements comprise but are not limited to an oxygen treatment scheme, a target percutaneous blood oxygen saturation (tcs 02) value, a percutaneous blood oxygen saturation (tcs 02) allowable deviation value, a percutaneous blood oxygen saturation (tcs 02) interval value, a carbon dioxide end-expiratory (PETCO2) value, a carbon dioxide end-expiratory (PETCO2) interval value, an initial flow value, intervention time, a flow correction interval and a flow correction gradient (index); specific data models of an oxygen treatment scheme, a target percutaneous blood oxygen saturation (tcs 02) value, a percutaneous blood oxygen saturation (tcs 02) allowable deviation value, a percutaneous blood oxygen saturation (tcs 02) interval value, a target end-tidal carbon dioxide (PETCO2) value, a target end-tidal carbon dioxide (PETCO2) interval value, an initial flow value, intervention time, a flow correction interval and a flow correction gradient (index) in the elements of the data model analysis control unit are preset in the data model analysis control unit, and the percutaneous blood oxygen saturation (tcs 02) value, the percutaneous blood oxygen saturation (tcs 02) allowable deviation value, the percutaneous blood oxygen saturation (tcs 02) interval value, the end-tidal carbon dioxide (PETCCO 2) value, the end-tidal carbon dioxide (PETCCO 2) interval value, the initial flow value and the oxygen inhalation time length can be set in a man-machine interaction interface in a personalized mode according to the state of a patient; the human-computer interaction interface at least comprises a target percutaneous blood oxygen saturation (tcs 02) setting key (or a touch screen key), a carbon dioxide end-tidal (PETCO2) value setting key (or a touch screen key), an oxygen inhalation time length setting key (or a touch screen key), a flow setting key (or a touch screen key), a low perfusion mode key (or a touch screen key) and an oxygen therapy scheme selection key (or a touch screen key).
2. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: the interval value of percutaneous oxyhemoglobin saturation (tcs 02) and the interval value of end-tidal carbon dioxide (PETCO2) are preset in a data model analysis control unit, the invention can automatically display the current hypoxia type on a human-computer exchange interface, judge whether carbon dioxide retention exists or not, and give an oxygen treatment scheme, a suggested oxyhemoglobin saturation interval value and an oxygen inhalation flow correction interval value, and only needs to set and select a reasonable oxygen treatment scheme on the human-computer interaction interface; the flow correction interval is divided into three regulation intervals of a low flow area, a medium flow area and a high flow area, a flow correction interval value is arranged in the data model, and as long as an initial flow value is set on a human-computer interaction interface, a reasonable oxygen treatment scheme is selected, and the data model analysis control unit automatically matches the corresponding flow correction interval and a transcutaneous oxygen saturation (tcs 02) interval value;
the data model analysis control unit is internally provided with a tertiary oxygen therapy scheme, wherein a value of end-tidal carbon dioxide (PETCO2) is normal, when the end-tidal carbon dioxide is not hypoperfused, a primary oxygen therapy scheme is started, when the value of the end-tidal carbon dioxide is abnormal and is higher than 6kpa (45mmhg), a secondary oxygen therapy scheme is started, when a patient has hypoperfusion symptoms, a hypoperfusion mode key (or a touch screen key) is pressed, the tertiary oxygen therapy scheme is started, and a transcutaneous blood oxygen saturation (tcs 02) monitoring unit and an end-tidal carbon dioxide (PETCO2) monitoring unit are used for carrying out double continuous monitoring on the dynamic transcutaneous blood oxygen saturation (tcs 02) value and the end-tidal carbon dioxide (PETCO2) value of the.
3. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: establishing a data model analysis control unit of a percutaneous oxyhemoglobin saturation (tcs 02) monitoring unit and a carbon dioxide end-expiratory (PETCO2) monitoring unit, intelligently judging the current hypoxia type of a patient, intelligently judging whether carbon dioxide retention exists, selecting a reasonable oxygen treatment scheme, suggesting an oxyhemoglobin saturation interval value and an oxygen uptake flow correction interval value, and selecting the reasonable oxygen treatment scheme by medical staff on a human-computer interaction interface; the initial oxygen flow and the oxygen treatment duration are only needed, when the state of an illness develops progressively, an oxygen treatment scheme adjustment suggestion can be automatically provided, warning information is sent out at the same time, medical staff are prompted to correct the oxygen treatment scheme, and the warning information is prompted or remotely transmitted to a clinical monitoring terminal on a human-computer interaction interface.
4. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: a target percutaneous blood oxygen saturation (tcs 02) value setting key (or a touch screen key), a carbon dioxide end-tidal (PETCO2) value setting key (or a touch screen key), an oxygen inhalation time length setting key (or a touch screen key), a flow setting key (or a touch screen key), a low perfusion mode key (or a touch screen key) and an oxygen treatment scheme selection key adopt electronic encoders; virtual keys can also be arranged on the microcomputer touch screen.
5. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: the data model analysis control unit takes the personalized target percutaneous blood oxygen saturation (tcs 02) value, the end-tidal carbon dioxide (PETCO2) value and the oxygen therapy scheme selection key as a tertiary control unit, the given target percutaneous blood oxygen saturation (tcs 02) value is provided with an allowable deviation value, and the target percutaneous blood oxygen saturation (tcs 02) allowable deviation value is set at the third-level control unit+1%～+Defined between 3%; the values of end-tidal carbon dioxide (PETCO2) are given in the interval 4.6kpa (35mmhg) < end-tidal carbon dioxide (PETCO2) < 6kpa (45 mmhg).
6. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: controlling the intervention time to be set between 0 and 60 min; preferably, the intervention time is calculated by taking the stable time of the dynamic percutaneous oxygen saturation (tcs 02) value and the end-expiratory carbon dioxide (PETCO2) interval value as a basis, when the dynamic percutaneous oxygen saturation (tcs 02) value overrides the control interval value and the state is stably maintained for 1-5 min, the data model analysis control unit reduces the oxygen output flow, when the dynamic percutaneous oxygen saturation (tcs 02) value is lower than the target percutaneous oxygen saturation (tcs 02) control interval value and the state is stably maintained and maintained for 0.5-3 min, the data model analysis control unit increases the oxygen output flow, and when the end-expiratory carbon dioxide (PETCO2) interval value is stably maintained for 10min, the oxygen treatment scheme of oxygen deficiency with hypercapnia is overridden.
7. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: when the value of end-tidal carbon dioxide (PETCO2) is normal, 4.6kpa (35mmhg) is more than or equal to Petco2 and less than or equal to 6kpa (45mmhg), the value of percutaneous blood oxygen saturation (tcs 02) is less than or equal to 94%, the system judges that the patient is low-tension hypoxia and does not accompany hypercapnia, the data model analysis control unit automatically matches the corresponding flow correction interval and blood oxygen saturation interval value according to the set initial flow value and the selected oxygen treatment scheme, and the data model analysis control unit intervenes in the automatic adjustment of the output flow of oxygen, strictly controls the upper limit and the lower limit of the output flow in the flow correction interval, and does not break through during the automatic adjustment.
8. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: when the end-tidal carbon dioxide (PETCO2) value is more than 6kpa (45mmhg) and the state is kept stable for 5min, the system judges that the patient is hypotonic hypoxia with hypercapnia, if the initial flow is in a medium flow area or a high flow area, the flow reduction gradient is adjusted to 2L/min, if the initial flow is in a low flow area, the flow reduction gradient is adjusted to 0.5L/min.
9. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by:
if the patient has low perfusion symptoms such as microcirculation disturbance, heart failure, myocardial infarction, shock and the like, a three-level oxygen treatment scheme is manually selected:
a. if the end-tidal carbon dioxide (PETCO2) value is more than 6kpa (45mmhg), whether the percutaneous blood oxygen saturation (tcs 02) interval is stable or not, the system automatically selects an oxygen treatment scheme of tissue hypoxia (or circulatory hypoxia) with hypercapnia, and the flow correction interval is adjusted to be a low flow area;
b. when the value of percutaneous blood oxygen saturation (tcs 02) is stable and is more than 90 percent and the value of end-tidal carbon dioxide (PETCO2) is stable and is less than 6kpa (45mmhg), the system automatically selects an oxygen treatment scheme that tissue hypoxia (or circulatory hypoxia) is not accompanied by hypercapnia, and the flow correction interval is adjusted to be a low flow area;
c. when the value of percutaneous blood oxygen saturation (tcs 02) is less than 90%, the value of 4.6kpa (35mmhg) < the value of end-tidal carbon dioxide (PETCO2) < 6kpa (45mmhg), the system automatically selects an oxygen treatment scheme with histochemical hypoxia (or circulatory hypoxia) and hypotonic hypoxia without hypercapnia, and the flow correction interval is adjusted to be a medium-flow area;
d. when the value of percutaneous blood oxygen saturation (tcs 02) is less than 90%, the value of end-tidal carbon dioxide (PETCO2) is more than 6kpa (45mmhg), and the state is stably kept for 1-5 min, the system automatically selects an oxygen treatment scheme flow correction interval with histochemical hypoxia (or circulatory hypoxia) and hypo-hypoxia accompanied by hypercapnia to adjust the flow correction interval to a low flow area or automatically restores the output flow value to an initial set flow value, automatic intervention regulation of output flow is stopped, the data model analysis control unit gives warning information to prompt medical personnel to correct the oxygen treatment scheme, and the warning information is prompted or remotely transmitted to a clinical monitoring terminal on a human-computer interaction interface.
10. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: the data model analysis control unit of the invention is internally provided with a blood liquid hypoxia mode, and is set to medium flow oxygen therapy (the flow value of medical advice is 3L/min-4L/min), and the flow correction interval is defined as 0.1L/min-4L/min, because the blood oxygen hypoxia blood gas change is special, but the clinical judgment is easy, and only a nursing staff needs to select the mode when in use.
11. An intelligent system for automatically providing an oxygen therapy regimen in accordance with claim 1 further characterized by: the data model analysis control unit of the invention is internally provided with a neonate mode which is set as low-flow oxygen therapy (the flow value of medical advice is between 0.5L/min and 2L/min), and the flow correction interval is defined as 0.1L/min to 2L/min.
12. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: when the end-tidal carbon dioxide (PETCO2) value is less than the critical value < 4.6kpa (35mmhg), the gradient is adjusted to the highest value of the interval flow, if the initial flow interval is a low flow area, the gradient is automatically adjusted to a medium flow area, or the automatic intervention is stopped to adjust the output flow, the data model analysis control unit gives out warning information to prompt medical personnel to correct the oxygen treatment scheme, and the warning information is prompted or remotely transmitted to a clinical monitoring terminal on a human-computer interaction interface.
13. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: the flow correction interval is divided into three adjustment intervals of a low flow area, a medium flow area and a high flow area, and specifically comprises the following steps: during low-flow oxygen treatment (the flow value of the doctor's advice is between 0.5L/min and 2L/min), the flow correction interval is defined to be between 0.1L/min and 2L/min, during medium-flow oxygen treatment (the flow value of the doctor's advice is between 3L/min and 4L/min), the flow correction interval is defined to be between 0.1L/min and 4L/min, and during high-flow oxygen treatment (the flow value of the doctor's advice is between 5L/min and 8L/min), the flow correction interval is defined to be between 0.1L/min and 8L/min.
14. An intelligent system for automatically providing an oxygen therapy regimen according to claim 1, further characterized by: the flow correction gradient is a flow value which is increased or decreased in each adjustment during the intervention flow adjustment, and is defined to be between 0.1L/min and 1L/min in a limited oxygen flow correction interval.
15. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: the parameter setting range of each of the construction elements of the control data model of the data model analysis control unit is preferably set to a target percutaneous blood oxygen saturation level (t) preset in the control data modelcs 02) allowed deviation value of+1%, intervention time, wherein the flow is reduced by 3min and the flow is increased by 0.5 min; the flow correction interval is defined as 0.5L/min-2L/min during low flow oxygen therapy (between 0.5L/min-2L/min), 1L/min-4L/min during medium flow oxygen therapy (between 3L/min-4L/min), and 1L/min-8L/min during high flow oxygen therapy (between 5L/min-8L/min); the flow correction gradient is 0.5L/min; the target percutaneous blood oxygen saturation (tcs 02) value, the initial flow value and the oxygen treatment duration are set individually according to individual difference and hypoxia degree of patients on a man-machine interaction interface.
16. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: when the end-tidal carbon dioxide (PETCO2) value exceeds a preset value and is higher than 10.6KPa (80 mmHg), the control data model is automatically switched to a secondary analysis control data model taking the end-tidal carbon dioxide (PETCO2) value as a leading factor, the flow correction interval of the end-tidal carbon dioxide (PETCO2) which is higher than 6KPa (45mmHg) is automatically defined to be 0.1L/min-2L/min, the intervention time is defined by 0.5min when the flow is reduced, and the increased flow is defined by 3 min; the flow correction gradient is 0.5L/min; the flow correction interval of the end-expiratory carbon dioxide (PETCO2) lower than 4kPa (30 n1 mHg) is automatically defined as 3L/min-4L/min, the flow is reduced by 3min, the flow is increased by 0.5min, and the flow correction gradient is 1L/min.
17. The intelligent system for automatically providing an oxygen therapy regimen of claim 1 further characterized by: the data model analysis control unit writes common oxygen treatment schemes of different hypoxia types and mixed hypoxia types into the control data model, medical staff only need to set and select a reasonable oxygen treatment scheme, initial oxygen flow and oxygen treatment duration on a human-computer interaction interface, and the data model analysis control unit automatically gives other factors such as a suggested blood oxygen saturation interval value, an oxygen uptake flow correction interval value and the like for the medical staff to select and apply; of course, according to individual differences of patients, medical staff can modify specific parameters such as oxygen inhalation flow value, oxygen inhalation time length and the like given by the data model analysis control unit at a human-computer interaction interface, and a more optimized and safer personalized treatment scheme is provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010958090.0A CN111991662B (en) | 2020-09-14 | 2020-09-14 | Intelligent system for automatically providing oxygen treatment scheme |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010958090.0A CN111991662B (en) | 2020-09-14 | 2020-09-14 | Intelligent system for automatically providing oxygen treatment scheme |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111991662A true CN111991662A (en) | 2020-11-27 |
| CN111991662B CN111991662B (en) | 2023-08-15 |
Family
ID=73469988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010958090.0A Active CN111991662B (en) | 2020-09-14 | 2020-09-14 | Intelligent system for automatically providing oxygen treatment scheme |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111991662B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115337025A (en) * | 2022-09-21 | 2022-11-15 | 广东省第二人民医院（广东省卫生应急医院） | Multi-bed remote measurement blood oxygen system with alarm function |
| CN116196522A (en) * | 2023-04-27 | 2023-06-02 | 首都医科大学宣武医院 | Respiration monitoring and adjusting system |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004000114A1 (en) * | 2002-06-20 | 2003-12-31 | University Of Florida | Perfusion monitor and system, including specifically configured oximeter probes and covers for oximeter probes |
| WO2004060443A2 (en) * | 2002-12-27 | 2004-07-22 | Scott Laboratories, Inc. | Apparatuses and methods for automatically assessing and monitoring a patient’s responsiveness |
| US20110257550A1 (en) * | 2010-03-20 | 2011-10-20 | Jay Choi | Method and Apparatus for Continuous Monitoring of Exhaled Carbon Dioxide |
| US20130060110A1 (en) * | 1997-01-27 | 2013-03-07 | Lawrence A. Lynn | System and method for automatic detection of a plurality of spo2 time series pattern types |
| US20150034082A1 (en) * | 2013-08-05 | 2015-02-05 | Covidien Lp | Oxygenation-ventilation methods and systems |
| CN104826204A (en) * | 2015-05-05 | 2015-08-12 | 阮雪红 | Intelligent servo oxygen therapy control system |
| CN105194759A (en) * | 2014-06-11 | 2015-12-30 | 三峡大学 | Infusion monitoring system for medical infusion bottles |
| US20180153440A1 (en) * | 2016-12-05 | 2018-06-07 | Medipines Corporation & The Regents Of The University Of California | System And Methods For Respiratory Measurements Using Breathing Gas Samples |
| WO2018180706A1 (en) * | 2017-03-31 | 2018-10-04 | 帝人ファーマ株式会社 | Oxygen supply device and method for controlling same |
| CN108721745A (en) * | 2018-06-15 | 2018-11-02 | 上海市北站医院 | A kind of novel monitoring PETCO2 automatic controls oxygen supply concentration device |
| CN108744190A (en) * | 2018-04-08 | 2018-11-06 | 西安汇智医疗集团有限公司 | A kind of with target blood oxygen levels is the intelligent oxygen therapy system being precisely controlled a little |
| US20190125999A1 (en) * | 2016-04-27 | 2019-05-02 | Linde Aktiengesellschft | System and method for delivering oxygen and preventing hypercapnia |
| CN110461397A (en) * | 2017-03-31 | 2019-11-15 | 帝人制药株式会社 | Oxygen therapy system |
| US20200016350A1 (en) * | 2018-07-11 | 2020-01-16 | General Electric Company | Ventilation control system and method utilizing patient oxygen saturation |
-
2020
- 2020-09-14 CN CN202010958090.0A patent/CN111991662B/en active Active
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130060110A1 (en) * | 1997-01-27 | 2013-03-07 | Lawrence A. Lynn | System and method for automatic detection of a plurality of spo2 time series pattern types |
| WO2004000114A1 (en) * | 2002-06-20 | 2003-12-31 | University Of Florida | Perfusion monitor and system, including specifically configured oximeter probes and covers for oximeter probes |
| WO2004060443A2 (en) * | 2002-12-27 | 2004-07-22 | Scott Laboratories, Inc. | Apparatuses and methods for automatically assessing and monitoring a patient’s responsiveness |
| US20110257550A1 (en) * | 2010-03-20 | 2011-10-20 | Jay Choi | Method and Apparatus for Continuous Monitoring of Exhaled Carbon Dioxide |
| US20150034082A1 (en) * | 2013-08-05 | 2015-02-05 | Covidien Lp | Oxygenation-ventilation methods and systems |
| CN105194759A (en) * | 2014-06-11 | 2015-12-30 | 三峡大学 | Infusion monitoring system for medical infusion bottles |
| CN104826204A (en) * | 2015-05-05 | 2015-08-12 | 阮雪红 | Intelligent servo oxygen therapy control system |
| US20190125999A1 (en) * | 2016-04-27 | 2019-05-02 | Linde Aktiengesellschft | System and method for delivering oxygen and preventing hypercapnia |
| US20180153440A1 (en) * | 2016-12-05 | 2018-06-07 | Medipines Corporation & The Regents Of The University Of California | System And Methods For Respiratory Measurements Using Breathing Gas Samples |
| CN110520043A (en) * | 2016-12-05 | 2019-11-29 | 梅迪平斯公司 | The system and method for carrying out respiration measurement using breathing gas sample |
| WO2018180706A1 (en) * | 2017-03-31 | 2018-10-04 | 帝人ファーマ株式会社 | Oxygen supply device and method for controlling same |
| CN110461397A (en) * | 2017-03-31 | 2019-11-15 | 帝人制药株式会社 | Oxygen therapy system |
| US20200094007A1 (en) * | 2017-03-31 | 2020-03-26 | Teijin Pharma Limited | Oxygen supply device and method for controlling same |
| CN108744190A (en) * | 2018-04-08 | 2018-11-06 | 西安汇智医疗集团有限公司 | A kind of with target blood oxygen levels is the intelligent oxygen therapy system being precisely controlled a little |
| CN108721745A (en) * | 2018-06-15 | 2018-11-02 | 上海市北站医院 | A kind of novel monitoring PETCO2 automatic controls oxygen supply concentration device |
| US20200016350A1 (en) * | 2018-07-11 | 2020-01-16 | General Electric Company | Ventilation control system and method utilizing patient oxygen saturation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115337025A (en) * | 2022-09-21 | 2022-11-15 | 广东省第二人民医院（广东省卫生应急医院） | Multi-bed remote measurement blood oxygen system with alarm function |
| CN116196522A (en) * | 2023-04-27 | 2023-06-02 | 首都医科大学宣武医院 | Respiration monitoring and adjusting system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111991662B (en) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111991663B (en) | 3-linked intelligent system capable of automatically providing oxygen treatment scheme | |
| JP5016595B2 (en) | Apparatus and method for controlling inspiratory oxygen concentration | |
| US8554298B2 (en) | Medical ventilator with integrated oximeter data | |
| EP2539001B1 (en) | Spontaneous breathing trial manager | |
| EP2611485B1 (en) | Ventilator apparatus and system for ventilation | |
| CN111991662A (en) | Intelligent system for automatically providing oxygen treatment scheme | |
| CN108310566B (en) | Intelligent control system for oxygen therapy/atomization therapy | |
| GB2442875A (en) | Drug delivery system | |
| CN108744190A (en) | A kind of with target blood oxygen levels is the intelligent oxygen therapy system being precisely controlled a little | |
| US20080236581A1 (en) | Method in a patient ventilating system | |
| CN108568018A (en) | A kind of intelligent controlling device and control method of target blood oxygen saturation | |
| WO2022076407A2 (en) | Respiratory distress management apparatus, system and method | |
| AU2011301986A1 (en) | Ventilation system | |
| WO2015144500A1 (en) | Medical intelligent ventilation system | |
| CN114949523A (en) | Intelligent breathing machine system with oxyhemoglobin saturation control function and control method | |
| CA2651287C (en) | A weaning and decision support system for mechanical ventilation | |
| US20220367029A1 (en) | Expert Module for Artificial Respiration and ECLS | |
| JPS6185963A (en) | Method and apparatus for controlling carbon dioxide in blood | |
| AU2009200284B2 (en) | A weaning and decision support system | |
| JPH11206884A (en) | Automatic weaning system for respirator applying fuzzy theory control and record medium recorded with automatic weaning program | |
| CN213609092U (en) | Simple continuous positive airway pressure device during single lung ventilation | |
| CN219022773U (en) | Disposable breathing auxiliary ventilation device | |
| Mi et al. | Effect of Different Oxygen Delivery Methods on Transcutaneous Oxygen Pressure and Fraction of Inspired Oxygen During Noninvasive Positive Pressure Ventilation | |
| CN117642199A (en) | Medical ventilation device, ventilation control method thereof, and storage medium | |
| Neumann et al. | SmartCare®/PS The automated weaning protocol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |